Sustained release formulation comprising octreotide and three linear polylactide-co-glycolide polymers
AssigneeNovartis AG
InventorsHolger Petersen, Markus Ahlheim
Life of this patent
Estimating the term…
Abstract
The present invention relates to sustained release formulations comprising as active ingredient octreotide or a pharmaceutically-acceptable salt thereof and three different linear polylactide-co-glycolide polymers (PLGAs).
Claims11
A sustained release pharmaceutical composition in the form of microparticles comprising as active ingredient octreotide or a pharmaceutically-acceptable salt thereof and a biocompatible polymer matrix which is a polymer blend comprising a first linear polylactide-co-glycolide polymer (PLGA) having a lactide:glycolide ratio of 85:15, a second linear PLGA having a lactide:glycolide ratio of 75:25 and a third linear PLGA having a lactide:glycolide ratio of 65:35, with each PLGA having an inherent viscosity below 0.9 dl/g in CHCl3, wherein octreotide is released from the composition at a rate which maintains plasma levels of octreotide within the therapeutic range for a period of between three and six months.
Dependencies are inferred from the claim text.